Company
Headquarters: Changsha, China
Employees: 1,273
CN¥7.75 Billion
CNY as of Jan. 1, 2026
US$1.10 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥3.05 B |
| EBITDA | CN¥607.1 M |
| Gross Profit TTM | CN¥2.25 B |
| Profit Margin | 15.36% |
| Operating Margin | 19.86% |
| Quarterly Revenue Growth | -3.00% |
Hunan Jiudian Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300705 wb_incandescent